We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Tumor Severity Linked to DNA Methylation

By Biotechdaily staff writers
Posted on 31 Oct 2003
Researchers using a microarray technique developed to evaluate DNA methylation in tumors have found that the degree of methylation often correlates with the seriousness of the tumor, which has important implications for diagnosing cancer and predicting a patient's prognosis.

Investigators at Ohio State University (Columbus, USA; www.osu.edu) examined the methylation levels at 19 sites spanning two adjoining regions--the promoter region and the neighboring first exon--of RASSF1A genes taken from 37 primary breast tumors, seven breast-cancer cell lines, and 10 samples of normal breast tissue. More...


They reported in the October 1, 2003, issue of Cancer Research that genes from normal breast cells showed low-to-moderate methylation in the exon and little or no methylation in the promoter. Nearly one-third of breast tumors sampled also showed low levels of methylation in the promoter region. The remaining tumor cells and all the breast-cancer cell lines showed moderate-to-high levels of methylation in the exon and various degrees of methylation in the promoter.

"Our findings show that progressive methylation occurs in tumors from patients and support the idea that methylation begins in the exons and extends into the promoter,” said senior author Dr.Tim Hui-Ming Huang, associate professor of human cancer genetics at Ohio State University.



Related Links:
Ohio State University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Portable POCT Blood Gas Analyzer
BD100
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.